Michael D Virata

Dr. Michael D Virata

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
Roman ShresthaRoman Shrestha
Roman Shrestha
JMJaimie P. Meyer
Jaimie P. Meyer
SSSheela Shenoi
Sheela Shenoi
AKAntoine Khati
Antoine Khati
FAFrederick L. Altice
Frederick L. Altice
Jeffrey A. WickershamJeffrey A. Wickersham
Jeffrey A. Wickersham
Introduction: Scaling up vaccination against COVID-19 is central to controlling the COVID-19 epidemic in the United States. Several vaccines are now approved for the prevention of COVID-19, but public concerns over safety and efficacy have heightened distrust and vaccine hesitancy. This is particularly concerning among people with HIV (PWH) who may be vulnerable to more severe COVID-19 disease. Here, we aimed to identify and understand COVID-19 vaccine hesitancy in a sample of PWH in the U.S. Methods: We conducted a cross-sectional online survey among PWH in the U.S. between 6 December 2020 and 8 January 2021. Measures included demographics, participants’ HIV and health-related attributes, COVID-19 history and experiences, COVID-19 vaccine-related concerns, and standardized measures of attitudes towards COVID-19 vaccines. Multivariate linear regression was used to identify factors associated with vaccine hesitancy in this sample. Results: Among the 1030 respondents, most were male (89.7%), White (66.0%), and identified as gay or lesbian (84.5%). Participants’ mean time living with HIV was 17.0 years (standard deviation (SD) = 11.1). The mean score for vaccine hesitancy was 1.5 (SD = 0.5; range: 1–5); 935 participants (90.8%) had a score greater than 1.0, indicating most participants had some degree of vaccine hesitancy. The final multivariate linear regression showed that greater vaccine hesitancy was associated with being Black (b = 0.149, p = 0.005), single (b = 0.070, p = 0.018), politically conservative (b = 0.157, p = 0.010), “anti-vaxxer” (b = 1.791, p < 0.001), concern about side effects (b = 0.226, p < 0.001), concern about safety (b = 0.260, p < 0.001), and being worried that the vaccine will not be effective (b = 0.169, p = 0.008) and they were being experimented on (b = 0.287, p < 0.001). Participants who were male White (b = −0.093, p = 0.008) and university graduates (b = −0.093, p < 0.001) and had a CD4 count of 200 cells/mm3 (b = −0.082, p = 0.048) and a liberal political orientation (b = −0.131, p < 0.001) were associated with lower vaccine hesitancy. Conclusions: Our findings provide important insights regarding COVID-19 vaccine hesitancy among PWH. Further efforts are required to understand how various social, political, and psychological factors contribute to COVID-19 vaccine hesitancy among key populations.

2 December 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
KHKristen Hysell
Kristen Hysell
RYRamsey Yusuf
Ramsey Yusuf
LBLydia Barakat
Lydia Barakat
MVMichael D Virata
Michael D Virata
GGGeliang Gan
Geliang Gan
BEBrinda Emu
Brinda Emu

4 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAmit C Achhra
Amit C Achhra
ECElizabeth Chan
Elizabeth Chan
SASerina Applebaum
Serina Applebaum
MGMaggie Guerrero
Maggie Guerrero
RHRitche Hao
Ritche Hao
LBLydia Barakat
Lydia Barakat
Background: Guidelines recommend annual anal cytology-based squamous cell carcinoma of anus (SCCA) screening for men who have sex with men with HIV aged ≥35 years (eligible population). The recommended threshold for high-resolution anoscopy (HRA) depends on its availability: low-threshold (any abnormal cytology) if availability is high and high-threshold (high-grade squamous intraepithelial lesion [HSIL] on cytology) if availability is low. Methods: This was a retrospective chart review (2018–2022) at academic HIV clinics. We evaluated (1) 5-year uptake of cytology-based SCCA screening in the eligible population and (2) estimated HSIL detection rate based on our current low-threshold criteria, and if high-threshold criteria were used for HRA referral. Results: Of 432 eligible individuals, only 219 (50.7%) had at least 1 and only 113 (26%) had >1 SCCA screening tests in a median follow-up of 4 years. Seventy-four (17.1%) individuals had at least 1 abnormal anal cytology during follow-up, of whom 56 (75.6%) underwent HRA. Increasing age (≥57 years) and history of smoking negatively correlated with ever receiving screening. Anal cytology (365 tests in 206 individuals) showed 17.5% “unsatisfactory” and 26.8% with any abnormal cytology (zero with HSIL) triggering HRA referral. Only 34 individuals (7.8% of screening eligible) were ever detected with HSIL. Strictly using high-threshold criteria for HRA referral would have led to no HRA or HSIL detection. Conclusions: We noted poor uptake of screening over time, particularly in older age groups. Importantly, anal cytology performed poorly as a triage test for HRA referral, with high rates of “unsatisfactory” samples and low sensitivity for detecting HSIL.

1 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MVMichael D Virata
Michael D Virata
SSSheela Shenoi
Sheela Shenoi
JLJoseph Ladines-Lim
Joseph Ladines-Lim
MVMerceditas S. Villanueva
Merceditas S. Villanueva
LBLydia A. Barakat
Lydia A. Barakat
There continue to be conflicting data regarding the outcomes of people with HIV (PWH) who have COVID-19 infection with most studies describing the early epidemic. We present a single site experience spanning a later timeframe from the first report on January 21, 2020 to January 20, 2021 and describe clinical outcomes and predictors of hospitalization among a cohort of PWH in an urban center in Connecticut, USA. Among 103 PWH with controlled HIV disease, hospitalization occurred in 33% and overall mortality was 1%. HIV associated factors (CD4 count, HIV viral suppression) were not associated with hospitalization. Chronic lung disease (OR: 3.35, 95% CI:1.28–8.72), and cardiovascular disease (OR: 3.4, 95% CI:1.27–9.12) were independently associated with hospitalization. An increasing number of non-communicable comorbidities increased the likelihood of hospitalization (OR: 1.61, 95% CI:1.22–2.13).

10 July 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
SASerina S Applebaum
Serina S Applebaum
ECElizabeth Chan
Elizabeth Chan
MVMichael D Virata
Michael D Virata
RHRitche Hao
Ritche Hao
LBLydia Barakat
Lydia Barakat
AAAmit C Achhra
Amit C Achhra
Guidelines now support anal squamous cell carcinoma (ASCC) screening in men who have sex with men (MSM) living with HIV (LWH) aged ≥35 years. There is limited data on screening in MSM LWH <35 years. Two academic HIV clinics in the Northeastern US. We retrospectively evaluated all anal cytology and high-resolution anoscopy (HRA; referral criteria: atypical cells of undetermined significance [ASC-US] or worse cytology) performed for MSM LWH between ages 18–34 from 2013 to 2023. We evaluated risk factors for abnormal cytology or histology, and prevalence of high-grade dysplasia (HSIL) and ASCC. Of 216 eligible MSM LWH, 111 (51%) were screened for ASCC at least once. Screened individuals had longer follow-up (median 4.0 vs 1.6 years) but were otherwise similar to unscreened individuals. Among 246 cytology tests, 19% were unsatisfactory and 31% abnormal, of which 1.2% reported HSIL. Of 23 HRAs following abnormal cytology, 10 (43%) revealed HSIL. Testing in response to symptoms was associated with abnormal results (OR 8.54; 95% CI 2.55–28.67). Human papillomavirus vaccination trended toward protection against abnormal results. We identified two cases of local ASCC, both in individuals with symptomatic condyloma and severe immunosuppression. Over 10 years, ASCC screening in MSM LWH <35 years was variable. Anal cytology had high unsatisfactory rates and poor correlation with histology. Despite high dysplasia prevalence among those undergoing HRA, ASCC was rare and diagnosed early from symptoms. Findings support excluding younger (≤34 years) MSM LWH from asymptomatic screening, and support symptom-driven testing to diagnose anal cancer early.

5 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MVMichael D Virata
Michael D Virata
SSSheela Shenoi
Sheela Shenoi
JLJoseph Ladines-Lim
Joseph Ladines-Lim
MVMerceditas S. Villanueva
Merceditas S. Villanueva
LBLydia A. Barakat
Lydia A. Barakat
Data regarding coronavirus disease (COVID-19) infection complications among people with HIV (PWH) are expanding but sometimes conflicting. This report presents the results of a retrospective review of 103 patients at a single urban academic health center with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study showed that hospitalization is related to host factors such as age 65 years or older with an increasing number of specific non-communicable disease comorbidities, and not to HIV-attributable factors.